Clevidipine butyrate injectable emulsion

Hospital Pharmacy

Volumn 43, Issue 11, 2008, Pages 903-909

  Cada, Dennis J ^a   Levien, Terri L ^a   Baker, Danial E ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLEVIDIPINE; CLEVIPREX; GLYCERYL TRINITRATE; ISOFLURANE; NICARDIPINE; NITROPRUSSIDE SODIUM; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; CLINICAL TRIAL; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STORAGE; DYSPNEA; EMULSION; ESSENTIAL HYPERTENSION; FLUSHING; HEADACHE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOTENSION; NAUSEA; NONHUMAN; POLYURIA; REVIEW; SIDE EFFECT; SINUS TACHYCARDIA; SYNCOPE; VOMITING;

EID: 57149106152     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1310/hpj4311-903     Document Type: Review

References (32)

1. Cleviprex [package insert]. Parsippany, NJ: The Medicines Company; August 2008.
2. Cardiovascular agents. Drug Facts and Comparisons. factsandcomparisons 4.0 [online]. 2008. Wolters Kluwer Health, Inc. Accessed August 20, 2008.
3. Yi X, Vivien B, Lynch C 3rd. Clevidipine blockade of L-type Ca2+ currents: steady-state and kinetic electrophysiological studies in guinea pig ventricular myocytes. J Cardiovasc Pharmacol. 2000;36(5):592-600.
4. Ericsson H, Fakt C, Hoglund L, et al. Pharmacokinetics and pharmacodynamics of clevidipine in healthy volunteers after intravenous infusion. Eur J Clin Pharmacol. 1999;55(1):61-67.
5. Ericsson H, Tholander B, Regårdh CG. In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolised by esterases, in different animal species and man. Eur J Pharm Sci. 1999;8(1):29-37.
6. Schwieler JH, Ericsson H, Löfdahl P, Thulin T, Kahan T. Circulatory effects and pharmacology of clevidipine, a novel ultra short acting and vascular selective calcium antagonist, in hypertensive humans. J Cardiovasc Pharmacol. 1999;34(2):268-274.
7. Ericsson H, Fakt C, Jolin-Mellgård A, et al. Clinical and pharmacokinetic results with a new ultrashort-acting calcium antagonist, clevidipine, following gradually increasing intravenous doses to healthy volunteers. Br J Clin Pharmacol. 1999;47(5):531-538.
8. Levy JH, Mancao MY, Gitter R, et al. Clevidipine effectively and rapidly controls blood pressure preoperatively in cardiac surgery patients: the results of the randomized, placebo-controlled efficacy study of clevidipine assessing its preoperative antihypertensive effect in cardiac surgery-1. Anesth Analg. 2007;105(4):918-925.
9. Kieler-Jensen N, Jolin-Mellgård A, Nordlander M, Ricksten SE. Coronary and systemic hemodynamic effects of clevidipine, an ultra-short-acting calcium antagonist, for treatment of hypertension after coronary artery surgery. Acta Anaesthesiol Scand. 2000;44(2):186-193.
10. Segawa D, Sjöquist PO, Nordlander M, Wang QD, Gonon A, Rydén L. Cardiac inotropic vs. chronotropic selectively of isradipine, nifedipine and clevidipine, a new ultrashort-acting dihydropyridine. Eur J Pharmacol. 1999;380(2-3):123-128.
11. Stephens CT, Jandhyala BS. Effects of fenoldopam, a dopamine D-1 agonist, and clevidipine, a calcium channel antagonist, in acute renal failure in anesthetized rats. Clin Exp Hypertens. 2002;24(4):301-313.
12. Wang QD, Segawa D, Ericsson H, Sjöquist PO, Johansson L, Rydén L. Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part I. J Cardiovasc Pharmacol. 2002;40(2):228-234.
13. Segawa D, Sjöquist PO, Wang QD, Gonon A, Rydén L. Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part II. J Cardiovasc Pharmacol. 2002; 40(3):339-345.
14. Odenstedt J, Månsson C, Grip L. Failure to demonstrate myocardial protective effects of the ultra short-acting calcium antagonist clevidipine in a closed-chest reperfusion porcine model. J Cardiovasc Pharmacol. 2004;44(4):407-415.
15. Gourine AV, Pernow J, Poputnikov DM, Sjöquist PO. Calcium antagonist clevidipine reduces myocardial reperfusion injury by a mechanism related to bradykinin and nitric oxide. J Cardiovasc Pharmacol. 2002;40(4):564-570.
16. Gourine A, Gonon A, Sjöquist PO, Pernow J. Short-acting calcium antagonist clevidipine protects against reperfusion injury via local nitric oxide-related mechanisms in the jeopardised myocardium. Cardiovasc Res. 2001;51(1):100-107.
17. Segawa D, Sjöquist PO, Wang QD, Gonon A, Nordlander M, Rydén L. Calcium antagonist protects the myocardium from reperfusion injury by interfering with mechanisms directly related to reperfusion: an experimental study with the ultrashort-acting calcium antagonist clevidipine. J Cardiovasc Pharmacol. 2000;36(3):338-343.
18. Ericsson H, Schwieler J, Lindmark B, Löofdahl P, Thulin T, Regårdh CG. Enantioselective pharmacokinetics of the enantiomers of clevidipine following intravenous infusion of the racemate in essential hypertensive patients. Chirality. 2001;13(3):130-134.
19. Bailey JM, Lu W, Levy JH, et al. Clevidipine in adult cardiac surgical patients: a dose-finding study. Anesthesiology. 2002;96(5):1086-1094.
20. Ericsson H, Bredberg U, Eriksson U, Jolin-Mellgård A, Nordlander M, Regårdh CG. Pharmacokinetics and arteriovenous differences in clevidipine concentration following a short- and a long-term intravenous infusion in healthy volunteers. Anesthesiology. 2000;92(4): 993-1001.
21. Vuylsteke A, Milner Q, Ericsson H, et al. Pharmacokinetics and pulmonary extraction of clevidipine, a new vasodilating ultrashort-acting dihydropyridine, during cardiopulmonary bypass. Br J Anaesth. 2000;85(5):683-689.
22. FDA accepts NDA filing for Cleviprex (clevidipine butyrate injectable emulsion) for the treatment of acute hypertension [news release]. Parsippany, NJ: The Medicines Company; September 14, 2007.
23. Singla N, Warltier DC, Lumb PD, Sladen RN; GPRO ESCAPE-2 Investigators. Clevidipine is effective in rapidly controlling elevated blood pressure post-operatively in cardiac surgery patients [abstract]. Anesthesiology. 2005;103(suppl):A292.
24. Singla N, Warltier DC, Gandhi SD, et al; ESCAPE-2 Study Group. Treatment of acute postoperative hypertension in cardiac surgery patients: an efficacy study of clevidipine assessing its postoperative antihypertensive effect in cardiac surgery-2 (ESCAPE-2), a randomized, double-blind, placebo-controlled trial. Anesth Analg. 2008;107(1):59-67.
25. Aronson S, Dyke CM, Kereiakes D, Cheung A, Stierer K, Newman M. Blood pressure control with clevidipine compared to nitroglycerin in the treatment of perioperative hypertension: primary results from the randomized ECLIPSE trial [abstract]. J Am Coll Cardiol. 2007;49(suppl A):391A.
26. Powroznyk AV, Vuylsteke A, Naughton C, et al. Comparison of clevidipine with sodium nitroprusside in the control of blood pressure after coronary artery surgery. Eur J Anaesthesiol. 2003;20(9):697-703.
27. Peacock WF, Varon J, Garrison N, et al. IV clevidipine for hypertension: safety, efficacy, and transition to oral therapy [abstract]. Ann Emerg Med. 2007;50:S8.
28. Peacock WFF, Varon J, Garrison NA, Ebrahimi R, Dunbar L, Pollack C. Clevidipine for severe hypertension in patients with renal dysfunction [abstract]. Crit Care Med. 2007;35(12)(suppl):A82.
29. Peacock WFF, Varon J, Garrison NA, Ebrahimi R, Dunbar L, Pollack C. Clevidipine for severe hypertension in heart failure: a VELOCITY trial analysis [abstract]. Crit Care Med. 2007;35(12)(suppl):A80.
30. Zhang JG, Dehal SS, Ho T, et al. Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006;34(5):734-737.
31. de Wolff MH, Leather HA, Wouters PF. Effect of clevidipine, an ultra-short acting 1,4-dihydropyridine calcium channel blocking drug, on the potency of isoflurane in rats and dogs. Eur J Anaesthesiol. 2000;17(8):506-511.
32. The Medicines Company's Cleviprex receives FDA approval [news release]. Parsippany, NJ: The Medicine Company; August 4, 2008. http://ir.themedicinescompany.com/relea sedetail.c fm ? ReleaseID=325959. Accessed August 5, 2008.